We investigated transarterial radioembolization (TARE) as a palliative measure and bridging-to-transplant therapy in hepatocellular carcinoma (HCC) patients. A total of 167 patients (50 bridging, 117 palliative) with 245 TARE procedures were assessed. Fourteen patients underwent subsequent liver transplantation (LT). Patients undergoing LT exhibited significantly prolonged progression-free survival (PFS) compared to those with bridging-without-transplant (p= 0.033). No significant differences were observed between patients with bridging-without-transplant and palliative cases (p= 0.116). Median overall survival (OS) post-TARE was 16.6 months, with estimated OS rates at 6/12 months of 82.0%/60.5%, respectively. Patients who underwent LT demonstrated statistically significantly longer OS compared to those with bridging-without-transplant (p= 0.001). No marked outcome distinctions were found between bridging-without-transplant and palliative groups. The findings underscored the superiority of LT over alternative treatments. TARE served as an important component in non-LT scenarios, allowing for subsequent therapeutic options. The study reflected the highly variable and complex situations of patients with HCC, emphasizing the need for further investigations to define an optimal multimodal approach.
本研究探讨经动脉放射栓塞术（TARE）作为肝细胞癌（HCC）患者姑息治疗及移植桥接治疗的应用价值。共纳入167例患者（50例桥接治疗，117例姑息治疗），累计实施245次TARE治疗。其中14例患者后续接受了肝移植（LT）。与仅接受桥接治疗未行移植的患者相比，接受肝移植患者的无进展生存期（PFS）显著延长（p=0.033）。而仅接受桥接治疗未行移植的患者与姑息治疗组间未见显著差异（p=0.116）。TARE术后中位总生存期（OS）为16.6个月，6个月及12个月预估OS率分别为82.0%和60.5%。接受肝移植患者的总生存期显著长于仅接受桥接治疗未行移植者（p=0.001）。桥接治疗未移植组与姑息治疗组间结局无显著差异。研究结果凸显了肝移植相较于其他治疗方式的优越性。在非肝移植治疗场景中，TARE作为重要治疗手段为后续治疗选择创造了条件。本研究反映了肝细胞癌患者临床情况的高度异质性与复杂性，强调需进一步开展研究以确立最优多模式治疗方案。
肿瘤(癌症)患者之家